Buflomedil
| |
| Names | |
|---|---|
| IUPAC name
4-(pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.054.393 |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C17H25NO4 | |
| Molar mass | 307.38 g/mol |
| Pharmacology | |
| C04AX20 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Buflomedil is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States. Currently available as trade name tablet Loftyl
Toxicity
This drug has been suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity.[1][2] In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options". The European Commission advised all member states to revoke marketing authorisation.[3]
Various adverse effects have been reported to the FDA.[4]
References
- ^ Medscape: http://www.medscape.com/viewarticle/753768
- ^ EMA: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/11/human_pha_detail_000045.jsp&mid=WC0b01ac058001d126
- ^ https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/RisikoBewVerf/a-f/buflomedil_durchf_beschluss.pdf?__blob=publicationFile&v=3
- ^ http://www.drugcite.com/?q=BUFLOMEDIL&s=&a=
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |